Klotho Neurosciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KLTO research report →
Companyklothoneuro.com
Klotho Neurosciences, Inc. , a biopharmaceutical company, develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates include AMI-101 for the treatment or prevention of Alzheimer's disease; and AMI-202 to treat and prevent amyotrophic lateral sclerosis.
- CEO
- Joseph A. Sinkule
- IPO
- 2022
- Employees
- 3
- HQ
- Omaha, NE, US
Price Chart
Valuation
- Market Cap
- $20.08M
- P/E
- -2.61
- P/S
- 0.00
- P/B
- 2.91
- EV/EBITDA
- -2.85
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -137.57%
- ROIC
- -75.09%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-6,150,372 · -769.36%
- EPS
- $-0.32 · -45614.29%
- Op Income
- $-5,540,236
- FCF YoY
- -566.23%
Performance & Tape
- 52W High
- $3.91
- 52W Low
- $0.11
- 50D MA
- $0.34
- 200D MA
- $0.63
- Beta
- 2.23
- Avg Volume
- 3.23M
Get TickerSpark's AI analysis on KLTO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 4, 26 | LeBlanc Jeff | other | 2,500,000 |
| Mar 4, 26 | El-Dada Riad Hussein | other | 350,000 |
| Mar 4, 26 | ZENTMAN SAMUEL M | other | 350,000 |
| Mar 4, 26 | Hirschman Shalom | other | 350,000 |
| Mar 4, 26 | McGarity Jon | other | 350,000 |
| Mar 4, 26 | SINKULE JOSEPH | other | 2,500,000 |
| Dec 10, 25 | McGarity Jon | other | 20,000 |
| Dec 10, 25 | ZENTMAN SAMUEL M | other | 20,000 |
| Dec 10, 25 | El-Dada Riad Hussein | other | 20,000 |
| Sep 25, 25 | SINKULE JOSEPH | other | 400,000 |
Our KLTO Coverage
We haven't published any research on KLTO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate KLTO Report →